Yifan Pharmaceutical Stock Forecast for 2023 - 2025 - 2030
Updated on 05/04/2024
Yifan Pharmaceutical Stock Forecast and Price Target
If the average price target of ¥19.00 set by distinguished experts for Yifan Pharmaceutical over the past few weeks is reached this year, there would be a potential upside of approximately 43.5% from the last closing price in May, 2024. This potential increase is based on a high estimate of ¥19.00 and a low estimate of ¥19.00. If you are looking to invest in the stock, it's important to research and compare different companies.
43.50% Upside
Yifan Pharmaceutical Fair Value Forecast for 2023 - 2025 - 2030
Yifan Pharmaceutical's Price has seen growth In the last zero years, going from ¥0.00 to ¥0.00 – a gain of 100.00% In the next year, analysts believe that Fair Value will reach ¥9.17 – an increase of 100.00%. For the next seven years, the forecast is forFair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600276 Stock Forecast | Jiangsu Hengrui Medicine | Buy |
15
|
¥46.16 | Buy/Sell | ¥56.49 | 16.98% |
| T14 Stock Forecast | Tianjin Pharmaceutical Da Ren ... | Outperform |
18
|
$34.99 | Buy/Sell | $1.70 | 30.89% |
| 600436 Stock Forecast | Zhangzhou Pientzehuang Pharmac... | Outperform |
18
|
¥237.24 | Buy/Sell | ¥302.86 | 19.10% |
| 000538 Stock Forecast | Yunnan Baiyao Group Co.,Ltd | Outperform |
18
|
¥57.25 | Buy/Sell | ¥65.39 | 11.79% |
| 1093 Stock Forecast | CSPC Pharmaceutical Group | Buy |
18
|
HK$6.76 | Buy/Sell | HK$9.50 | 37.57% |
Yifan Pharmaceutical Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Yifan Pharmaceutical's Revenue has decreased from ¥5.40B to ¥4.07B – a 24.67% drop. In the next year, analysts believe that Revenue will reach ¥4.50B – an increase of 10.57%. For the next seven years, the forecast is forRevenue to grow by 6.54%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 000999 Stock Forecast | China Resources Sanjiu Medical... | Buy |
18
|
¥59.97 | Buy/Sell | ¥65.95 | 13.62% |
| 600085 Stock Forecast | Beijing Tongrentang | Outperform |
16
|
¥42.33 | Buy/Sell | ¥61.18 | 27.57% |
| 600196 Stock Forecast | Shanghai Fosun Pharmaceutical ... | Outperform |
16
|
¥23.67 | Buy/Sell | ¥33.57 | 20.83% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 002294 Stock Forecast | Shenzhen Salubris Pharmaceutic... | Buy |
18
|
¥31.92 | Buy/Sell | ¥35.65 | 15.91% |
| 600079 Stock Forecast | Humanwell Healthcare (Group) | Buy |
0
|
¥20.25 | Buy/Sell | ¥32.49 | -100.00% |
| 000513 Stock Forecast | Livzon Pharmaceutical Group | Outperform |
18
|
¥36.98 | Buy/Sell | ¥39.23 | 11.41% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600518 Stock Forecast | Kangmei Pharmaceutical | - |
6
|
¥1.99 | Buy/Sell | ¥25.97 | -100.00% |
| 300146 Stock Forecast | Byhealth | Outperform |
15
|
¥15.84 | Buy/Sell | ¥26.39 | 29.42% |
| 002262 Stock Forecast | Jiangsu Nhwa Pharmaceutical Co... | Buy |
18
|
¥25.01 | Buy/Sell | ¥31.34 | 23.95% |
Yifan Pharmaceutical EBITDA Forecast for 2023 - 2025 - 2030
Yifan Pharmaceutical's EBITDA has decreased by 77.46% In the last three years, from ¥1.19B to ¥268.03M. In the next year, analysts are expecting an increase in EBITDA, predicting it will reach ¥862.64M – an increase of 221.84%. The Yifan Pharmaceutical forecast is for EBITDA to reach ¥1.17B or grow by 335.07%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 900904 Stock Forecast | Shanghai Shenqi Pharmaceutical... | - |
13
|
$6.53 | Buy/Sell | $0.00 | -100.00% |
| 600062 Stock Forecast | China Resources Double-Crane P... | Buy |
16
|
¥21.77 | Buy/Sell | ¥26.00 | 18.24% |
| 600380 Stock Forecast | Joincare Pharmaceutical Group ... | Buy |
18
|
¥11.61 | Buy/Sell | ¥14.72 | 26.79% |
Yifan Pharmaceutical EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Yifan Pharmaceutical's EBIT has decreased from ¥1.01B to ¥20.93M – a 97.94% drop! For next year, the 2 analysts predict EBIT of ¥458.03M, which would mean an increase of 2088.39%. Over the next seven years, the pros' prediction is EBITof ¥894.04M, which would mean a seven-year growth forecast of 4171.55%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 002773 Stock Forecast | Chengdu Kanghong Pharmaceutica... | Buy |
11
|
¥21.70 | Buy/Sell | ¥24.00 | -100.00% |
| 600867 Stock Forecast | Tonghua Dongbao Pharmaceutical | Buy |
18
|
¥10.09 | Buy/Sell | ¥14.25 | 45.49% |
| 603858 Stock Forecast | Shandong Buchang Pharmaceutica... | - |
18
|
¥16.85 | Buy/Sell | ¥0.00 | -100.00% |
Yifan Pharmaceutical EPS Price Prediction Forecast for 2023 - 2025 - 2030
Yifan Pharmaceutical's EPS has seen growth In the last zero years, going from ¥0.00 to ¥0.00 – a gain of 100.00% In the next year, analysts believe that EPS will reach ¥0.47 – an increase of 100.00%. For the next seven years, the forecast is forEPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 000623 Stock Forecast | Jilin Aodong Pharmaceutical Gr... | Buy |
16
|
¥15.28 | Buy/Sell | ¥0.00 | 48.36% |
| 600422 Stock Forecast | KPC Pharmaceuticals,Inc | Buy |
18
|
¥22.72 | Buy/Sell | ¥28.00 | 10.08% |
| 000766 Stock Forecast | Tonghua Golden-Horse Pharmaceu... | - |
11
|
¥17.16 | Buy/Sell | ¥33.00 | -100.00% |
.jpg)